Bicycle Therapeutics plc (50BA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has a cash flow conversion efficiency ratio of -0.032x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-19.35 Million ≈ $-22.62 Million USD) by net assets (€609.98 Million ≈ $713.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bicycle Therapeutics plc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bicycle Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 50BA current and long-term liabilities for a breakdown of total debt and financial obligations.
Bicycle Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicycle Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ingram Micro Bilisim Sistemleri A.S.
IS:INGRM
|
0.002x |
|
Starz Entertainment LLC
NASDAQ:STRZ
|
-0.033x |
|
Panca Budi Idaman Tbk PT
JK:PBID
|
0.025x |
|
Jiangsu Zhongshe Group Co Ltd
SHE:002883
|
0.010x |
|
Alvopetro Energy
V:ALV
|
0.126x |
|
908 Devices Inc
NASDAQ:MASS
|
0.009x |
|
Salmon Evolution Holding AS
OL:SALME
|
-0.040x |
|
Sonmez Filament Sentetik Iplik ve Elyaf Sanayi AS
IS:SONME
|
0.017x |
Annual Cash Flow Conversion Efficiency for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bicycle Therapeutics plc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Bicycle Therapeutics plc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €609.98 Million ≈ $713.13 Million |
€-249.68 Million ≈ $-291.90 Million |
-0.409x | -97.07% |
| 2024-12-31 | €793.06 Million ≈ $927.17 Million |
€-164.72 Million ≈ $-192.58 Million |
-0.208x | -76.51% |
| 2023-12-31 | €370.93 Million ≈ $433.66 Million |
€-43.65 Million ≈ $-51.03 Million |
-0.118x | +63.00% |
| 2022-12-31 | €270.78 Million ≈ $316.57 Million |
€-86.11 Million ≈ $-100.67 Million |
-0.318x | -644.30% |
| 2021-12-31 | €346.25 Million ≈ $404.81 Million |
€-14.79 Million ≈ $-17.30 Million |
-0.043x | +77.07% |
| 2020-12-31 | €95.46 Million ≈ $111.60 Million |
€-17.79 Million ≈ $-20.80 Million |
-0.186x | +39.30% |
| 2019-12-31 | €93.20 Million ≈ $108.96 Million |
€-28.61 Million ≈ $-33.45 Million |
-0.307x | -182.21% |
| 2018-12-31 | €-69.83 Million ≈ $-81.63 Million |
€-26.08 Million ≈ $-30.49 Million |
0.373x | -- |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more